The Pharmaceutical Influence, Clinical Analysis, and Managerial Treatment of Bisphosphonates-associated Osteonecrosis
Loading...
Authors
Murphy, M. Timothy
Issue Date
2006
Type
Thesis
Language
en_US
Keywords
Alternative Title
Abstract
Incidence of skeletal diseases has increased concomitantly with other degenerative
diseases. In response, pharmaceutical companies have begun using bisphosphonates, which
were originally employed in the industrial sector over a century (Licata, 2005). However, since
bisphosphonates also have a strong affinity to hydroxyapatite, they are useful in the medical field
(Tech Rpt of Zometa®, 2005). Yet, post-market research has uncovered adverse effects
associated with bisphosphonate therapy. These side-effects are only associated with the
nitrogen-based bisphosphonate derivatives and are part of a larger disorder called
bisphosphonate-associated osteonecrosis (BON). The complications associated with BON
include oral lesions, non-healing gingival wounds, and osteonecrosis of the jaw, yet these side-effects
are only observed in 0.7 out of everyone 1 00,000 patients undergoing bisphosphonate
therapy (ADASCA, 2006). Treatment options for symptoms of BON are very limited, because
of its rarity and infrequency. Beside sequestrectomies, no treatments have been successful after
BON fully develops. Therefore, a preventive treatment plan is the most effective measure in the
fight against BON. The preventive care hinges on cooperation between both dentists and
physicians. Without proper communication between clinicians, the probability of developing
BON increases. To decrease the chance of developing BON, patient's cancer treatments and
osteoporosis therapies should be approved by both practitioners. This protocol will reduce the
amount of future oral trauma, which is one of the steps of the pathobiological development of
BON.
Description
vi, 50 p.
Citation
Publisher
License
U.S. copyright laws protect this material. Commercial use or distribution of this material is not permitted without prior written permission of the copyright holder. All rights reserved.